| Literature DB >> 35223462 |
Giacomo Da Col1, Fabio Del Ben2, Michela Bulfoni3, Matteo Turetta4, Lorenzo Gerratana2,5, Serena Bertozzi6, Antonio Paolo Beltrami2, Daniela Cesselli2,3.
Abstract
BACKGROUND: The purpose of the present work was to test whether quantitative image analysis of circulating cells can provide useful clinical information targeting bone metastasis (BM) and overall survival (OS >30 months) in metastatic breast cancer (MBC).Entities:
Keywords: circulating tumor cells; data science; image analysis; liquid biopsy; machine learning
Year: 2022 PMID: 35223462 PMCID: PMC8866934 DOI: 10.3389/fonc.2022.725318
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Overview of data analysis workflow.
Demographic and clinicopathological features of the 45 MBC patients analyzed.
|
| |
| - MEDIAN ( | 54 (31–78) |
|
| |
| Ductal | 86.6% |
| Lobular | 11.2% |
| Ductal and Lobular | 2.2% |
|
| |
| Luminal | 44.4% |
| HER2+ | 31.1% |
| Triple negative | 20.0% |
| N.A. | 4.4% |
|
| |
| 1 | 31.1% |
| 2 | 17.8% |
| >2 | 51.1% |
|
| |
| Bone | 66.7% |
| Liver | 44.4% |
| Lymphonodes | 33.3% |
| SNC | 11.1% |
| Skin | 20.0% |
| Lung | 35.5% |
*Patients may have more than one site involved.
Distribution of cells in patients.
| Patient id | no. of cells | CD45pos | eCTC | Patient id | no. of cells | CD45pos | eCTC |
|---|---|---|---|---|---|---|---|
|
| 11 | 1 | 1 | ||||
|
| 125 | 13 | 1 |
| 25 | 12 | 9 |
|
| 53 | 6 | 31 |
| 77 | 12 | 4 |
|
| 80 | 18 | 51 |
| 79 | 41 | 1 |
|
| 48 | 9 | 1 |
| 87 | 64 | 2 |
|
| 73 | 30 | 11 |
| 60 | 12 | 7 |
|
| 31 | 6 | 2 |
| 21 | 6 | 4 |
|
| 21 | 7 | 5 |
| 84 | 35 | 5 |
|
| 40 | 13 | 6 |
| 7 | 1 | 2 |
|
| 21 | 8 | 7 |
| 38 | 26 | 3 |
|
| 46 | 0 | 16 |
| 24 | 3 | 0 |
|
| 52 | 33 | 2 |
| 15 | 0 | 2 |
|
| 12 | 0 | 9 |
| 98 | 9 | 8 |
|
| 94 | 14 | 3 |
| 67 | 51 | 1 |
|
| 47 | 7 | 0 |
| 127 | 66 | 3 |
|
| 98 | 39 | 2 |
| 101 | 27 | 18 |
|
| 11 | 5 | 0 |
| 72 | 26 | 16 |
|
| 56 | 23 | 4 |
| 35 | 24 | 0 |
|
| 32 | 23 | 1 |
| 15 | 0 | 11 |
|
| 144 | 25 | 62 |
| 57 | 11 | 3 |
|
| 63 | 32 | 1 |
| 62 | 17 | 6 |
|
| 72 | 30 | 8 |
| 49 | 15 | 0 |
|
| 111 | 25 | 5 |
| 57 | 21 | 10 |
|
|
|
|
|
CD45pos, CD45-positive cells; eCTC, epithelial circulating tumor cells.
Bold is the total (sum) of each column.
Best features ranked by information gain, with respect to overall survival and bone metastasis.
| OVERALL SURVIVAL | |||
|---|---|---|---|
| eCTC | CD45 positive cells | ||
| FEATURES | SCORE | FEATURES | SCORE |
| circularityOV_brightfield_25th | 0.237* | circularityOV_brightfield_SD | 0.203* |
| perimeter_fitc_25th | 0.215* | circularityOV_fitc_25th | 0.178* |
| circularity_brightfield_25th | 0.189* | circularity_brightfield_25th | 0.169* |
| mean_intensity_bgsub_apc_SD | 0.184* | circularity_fitc_25th | 0.163* |
| circularity_brightfield_mean | 0.174* | mean_intensity_bgsub_pe_25th | 0.154* |
| circularity_apc_mean | 0.146 | perimeter_fitc_75th | 0.146 |
| circularityOV_pe_75th | 0.146 | circularityOV_fitc_mean | 0.146 |
| max_intensity_brightfield_median | 0.142 | diameter_brightfield_25th | 0.133 |
| diameter_apc_median | 0.138 | circularity_fitc_SD | 0.130 |
| circularity_dapi_25th | 0.133 | circularityOV_brightfield_median | 0.121 |
|
| |||
|
|
| ||
|
|
|
|
|
| diameter_fitc_median | 0.211* | diameter_pe_SD | 0.203* |
| % of eCTC | 0.189* | circularity_fitc_SD | 0.203* |
| perimeter_apc_25 th | 0.189* | perimeter_pe_SD | 0.203* |
| circularity_fitc_SD | 0.177* | perimeter_fitc_SD | 0.163 |
| circularityOV_fitc_SD | 0.177* | perimeter_brightfield | 0.155 |
| max_intensity_apc_SD | 0.177* | circularity_apc_75th | 0.153 |
| circularityOV_brightfield_SD | 0.177* | circularityOV_brightfield_75th | 0.139 |
| mean_intensity_bgsub_apc_25th | 0.170 | circularity_apc_25th | 0.139 |
| diameter_apc_mean | 0.167 | circularity_pe_median | 0.134 |
| diameter_apc_75th | 0.167 | circularityOV_pe_75th | 0.134 |
Each feature is described by the parameter, the channel of collection (brightfield, fitc, pe or apc) and descriptive statistics feature (mean, standard deviation, median, 25th or 75th percentile). SD, standard deviation; mean_intensity_bgsub, mean intensity after background subtraction; fitc, epithelial marker expression; pe, mesenchymal marker expression; apc, CD45 expression; DAPI, nuclear staining. *features subsequently selected for the combined approach (see Experimental Setup).
Figure 2Kaplan–Meier curves of MBC patients stratified according to the circularity of eCTC (left) and CD45 positive cells (right). P-values were calculated by Log Rank test.
Contingency tables of prediction of bone metastasis based on a single variable derived from either eCTC (left) or CD45-positive cells (right).
| eCTC-based prediction Actual | CD45pos-based prediction Actual | |||||||
|---|---|---|---|---|---|---|---|---|
| BM+ | BM− | BM+ | BM− | |||||
|
| BM+ | 19 | 5 |
| BM+ | 10 | 1 |
|
| 0.79 | 0.91 | |||||||
| BM− | 11 | 10 |
| BM− | 20 | 14 |
| |
| 0.48 | 0.41 | |||||||
|
|
|
|
|
|
| |||
| 0.63 | 0.67 | 0.64 | 0.33 | 0.93 | 0.53 | |||
Columns indicate the actual positive and negative patients, while the rows indicate the predicted positives and negatives patients. BM+, presence of bone metastasis; BM−, absence of bone metastasis, PPV, positive predictive value; NPV, negative predictive value.
Features identified by the naïve Bayes approach as the most informative to predict overall survival and bone metastasis considering eCTC features alone (left), CD45pos alone (center) or both (right).
| eCTC | OVERALL SURVIVAL | eCTC & CD45pos |
|---|---|---|
| CD45pos | ||
| circularityOV_brightfield_25th | circularityOV_brightfield_SD | eCTC: perimeter_fitc_25th |
| perimeter_fitc_25th | circularity_fitc_25th | eCTC: circularity_brightfield_mean |
| circularity_apc_mean | mean_intensity_bgsub_pe_25th | CD45pos cells: circularityOV_brightfield_SD |
| circularityOV_pe_75th | CD45pos cells: mean_intensity_bgsub_pe_25th | |
| max_intensity_brightfield_median | ||
|
|
|
|
| perimeter_apc_25th | circularity_fitc_SD | eCTC: perimeter_apc_25th |
| percentage of eCTC | circularity_apc _75th | eCTC: percentage of eCTC |
| circularityOV_brightfield_SD | eCTC: | |
| max_intensity_apc_SD | circularityOV_brightfield_SD |
SD, standard deviation; mean_intensity_bgsub, mean intensity after background subtraction; fitc, epithelial marker expression; pe, mesenchymal marker expression; apc, CD45 expression.
Figure 3Kaplan–Meier curves of the MBC patients stratified in OS <= 30 months (blue curve) or >30 months (orange curves) according to the naïve Bayes analysis conducted taking into consideration eCTC (left panel), CD45pos (central panel) or eCTC+C45pos (right panel).
Contingency tables of the prediction of bone metastases adopting a machine learning approach taking into consideration only eCTC (top), only CD45-positive cells (middle) or both (bottom).
| eCTC | ||||
|---|---|---|---|---|
| Actual | ||||
| Pos | Neg | |||
| Predicted | Pos | 26 | 0 | PPV = 1 |
| Neg | 4 | 15 | NPV = 0.79 | |
| Sensitivity | Specificity | Accuracy | ||
| 0.87 | 1 | 0.91 | ||
|
| ||||
|
| ||||
|
|
| |||
| Predicted | Pos | 26 | 3 | PPV = 0.9 |
| Neg | 4 | 12 | NPV = 0.75 | |
| Sensitivity | Specificity | Accuracy | ||
| 0.87 | 0.80 | 0.84 | ||
|
| ||||
|
| ||||
|
|
| |||
| Predicted | Pos | 26 | 0 | PPV = 1 |
| Neg | 4 | 15 | NPV = 0.79 | |
| Sensitivity | Specificity | Accuracy | ||
| 0.87 | 1 | 0.91 | ||
PPV, positive predictive value; NPV, negative predictive value.